NCT01931176View on ClinicalTrials.gov

Evaluating the Safety and Immune Response to a Dengue Virus Vaccine in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

May 31, 2015

Conditions
Dengue
Interventions
BIOLOGICAL

rDEN2Δ30-7169 vaccine

Administered at a dose of 10\^3 plaque-forming units (PFU); delivered by subcutaneous injection in the deltoid region of the upper arm

BIOLOGICAL

Placebo

Delivered by subcutaneous injection in the deltoid region of the upper arm

Trial Locations (1)

21205

John Hopkins Bloomberg School of Public Health - Center for Immunization Research (CIR), Baltimore

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01931176 - Evaluating the Safety and Immune Response to a Dengue Virus Vaccine in Healthy Adults | Biotech Hunter | Biotech Hunter